Convatec Group PLC (CTEC), the FTSE-listed medical technology company, has disclosed the purchase of ordinary shares across four trading days in early November 2026, as part of its ongoing $200 million share buyback programme announced on 4 August 2026. The transactions were executed through Morgan Stanley & Co. International plc and cover purchases made between 2 and 6 November 2026. All purchased shares will be held in treasury, reducing the effective float available to the market. The disclosure updates investors on the total voting rights figure now applicable under FCA transparency rules.

Key Points

  • Convatec Group PLC (CTEC) — FTSE-listed medical technology company
  • The company purchased ordinary shares on four separate days between 2 and 6 November 2026 as part of its $200m buyback programme
  • The highest price paid across the period was 250.20p per share on 6 November 2026; total shares purchased across the four days exceeded 1.1 million
  • Investors should watch the pace of buyback deployment relative to the $200m programme ceiling and any further treasury share disclosures

Convatec Purchases More Than 1.1 Million Shares Across Four Days via Morgan Stanley

According to the announcement, Convatec purchased 3,336 shares on 2 November 2026 at a volume weighted average price of 244.50p, followed by 425,108 shares on 3 November at 243.33p, 184,297 shares on 4 November at 243.24p, and 493,836 shares on 6 November at 247.92p. The highest single price paid was 250.20p on 6 November, while the lowest across the period was 240.00p on 4 November. Morgan Stanley & Co. International plc acted as the executing broker on behalf of the company throughout all four sessions under the terms of the programme.

Treasury Share Position and Total Voting Rights Following the November Purchases

Following these purchases, Convatec now holds 138,676,968 ordinary shares of 10 pence each in treasury. The total number of ordinary shares in issue, excluding treasury shares, stands at 1,911,112,591. Under FCA Disclosure Guidance and Transparency Rules, this figure of 1,911,112,591 represents the total voting rights in the company and serves as the denominator shareholders must use when calculating whether they are required to notify a change in their interest in Convatec. The announcement was made by Company Secretary James Kerton.

$200m Buyback Programme Context and Convatec's Medical Technology Business

Convatec Group is a global medical technology business focused on products and services for the management of chronic conditions, including advanced wound care and ostomy care. The company launched its $200 million buyback programme on 4 August 2026, and these November transactions represent continued deployment of that capital. Investors tracking the programme's progress will note that full details of individual transactions executed by Morgan Stanley are available via the London Stock Exchange's RNS document service, in compliance with Article 5(1)(b) of UK-retained EU Market Abuse Regulation.